SCHEMBL15316007

SCHEMBL15316007

c1ccc(-c2nccn2-c2c(-c3cccc4ccccc34)cccc2-c2cccc3ccccc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.43
HTR2A P28223 1/20 0.43
KDR P35968 12/20 0.43
MAPK9 P45984 1/20 0.43
MAPK10 P53779 1/20 0.43
P2RX4 Q99571 1/20 0.42
ENPP3 O14638 1/20 0.40
ENPP1 P22413 1/20 0.40
FLT1 P17948 2/20 0.40
FLT4 P35916 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
MAPK1 P28482 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15316084 0.86 KDM4E (0.45) HTR2CHTR2AKDRMAPK9MAPK10
SCHEMBL15315995 0.86 KDR (0.47) HTR2CHTR2AKDRMAPK9MAPK10
SCHEMBL25564159 0.84 KDR (0.46) KDRMAPK9MAPK10FLT1FLT4
SCHEMBL27659057 0.80 P2RX4 (0.46) KDRMAPK9MAPK10P2RX4FLT1
SCHEMBL15315987 0.79 ALOX5 (0.42) KDRFLT1FLT4MAPTATM
SCHEMBL15316045 0.78 HSD11B1 (0.39) KDRMAPK9MAPK10P2RX4FLT1
SCHEMBL15315985 0.78 KDR (0.44) KDRMAPK9MAPK10FLT1FLT4
SCHEMBL19961723 0.77 HTR2C (0.46) HTR2CHTR2AMAPK9MAPK10P2RX4
SCHEMBL3816909 0.77 TOP1 (0.42) KDRFLT1FLT4KDM4E
SCHEMBL12797971 0.75 KDR (0.43) KDRMAPK9MAPK10FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130270541-A1 IMIDAZOLE COMPOUND PRODUCTION METHOD, IMIDAZOLE COMPOUND, IMIDAZOLE-BASED COMPOUND, ORGANIC METAL COMPLEX, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2013-10-17 US disclosed
US-20130270541-A1 IMIDAZOLE COMPOUND PRODUCTION METHOD, IMIDAZOLE COMPOUND, IMIDAZOLE-BASED COMPOUND, ORGANIC METAL COMPLEX, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2013-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130270541-A1 IMIDAZOLE COMPOUND PRODUCTION METHOD, IMIDAZOLE COMPOUND, IMIDAZOLE-BASED COMPOUND, ORGANIC METAL COMPLEX, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE NFXL1, NFE2L2, ZC3HAV1L HTR2C 2204/4885HTR2A 3865/4885KDR 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.